Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
BitMEX Launches the 24/7 TradFi Campaign Featuring a 50,000 USDT Prize Pool
-
Helsinn appoints Giacomo Braglia to the Board of Directors
-
Allegro MicroSystems to Announce Fourth Quarter and Fiscal Year 2026 Financial Results
-
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
-
Duncan-Parnell Joins GeoCue Global Distribution Network to Expand Access to TrueView LiDAR and LP360 Software Across the Southeast
-
FX Junction Among the Top 3 Social Trading Platforms in Industry Review
-
Bilibili Inc. to Hold Annual General Meeting on June 17, 2026
-
FBS Global Limited Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
-
Gildan Activewear Announces Date for First Quarter 2026 Financial Results
-
Edison Initiates Coverage on One and One Green Technologies with a US$8.3 Base Case Valuation
-
Correction: Fixing of coupon rates - Nykredit Realkredit A/S
-
Results of the Annual General Meeting of ISS A/S
-
FIXING OF COUPON RATES - Nykredit Realkredit A/S
-
Zoomex Launches ZoomexStocks: Trade Global Equities with USDT + Limited-Time Fee Rebate Campaign
-
JD.com Files Its Annual Report on Form 20-F
-
eToro's AI investing companion Tori gets real-time X intelligence, powered by Grok 4.2
-
Hemp Hop’s First 420 Deals in Houston, TX - Buy 3 Get 1 Free 2026
-
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
-
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
-
Ealixir Reports Full Year 2025 Results
-
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026
-
Zanskar Closes $40M in Novel Development Capital Financing, structured to scale to $100M
-
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
-
EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026
-
Clarification – distribution of the press release dated Thursday 16 April 2025
-
Exodus Expands XRP and RLUSD Support, in Collaboration with Ripple
-
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
-
Manhattan Bridge Capital, Inc. Reports First Quarter Results for 2026
-
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
-
Bilibili Publishes 2025 Environmental, Social and Governance Report
-
Announcement of AGM Results
-
ATUM Welcomes Gavin Barnard, Ph.D., as Chief Scientific Officer
-
Redefining Enterprise Engagement at InnoEX Hong Kong: Aurora Mobile's EngageLab Unveils AI-First Solutions
-
CareCloud Reaffirms Guidance Following Capital Structure Simplification, Capping a Decade of Transformation
-
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
-
CoinShares Appoints Paul Grinberg as Chairman and Announces Full Board of Directors Following Nasdaq Listing
-
HRCI Introduces Its Next Chapter with a New Brand Identity
-
Eshallgo Announces 1 for 16 Share Consolidation
-
Remedy Plan Therapeutics Announces Multiple Presentations at the AACR Annual Meeting 2026
-
Abaxx to Launch World’s First Exchange-Traded Solar Futures Contract
-
Balchem Corporation Announces Quarterly Conference Call for First Quarter 2026 Financial Results on April 30, 2026
-
Soleo Health Appoints Joy Rowan as New Senior Vice President of Sales to Drive Strategic Growth Initiatives
-
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
-
Guardian Capital Announces April 2026 Cash Distributions for Guardian Capital ETFs
-
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
-
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
-
Cielo Closes Strategic Asset Acquisition and Announces Intention to Appoint Chief Operating Officer and Chief Development Officer
-
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
-
Nula Therapeutics Launches with up to $20 Million ARPA-H Award to Advance a New Class of Medicines Targeting the Nuclear Envelope of Cells
-
Canadian Premium Sand Inc. Announces Strategic Review

